Head to Head Analysis: Cardiff Oncology (NASDAQ:CRDF) and BioStem Technologies (OTCMKTS:BSEM)

BioStem Technologies (OTCMKTS:BSEM) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Profitability

This table compares BioStem Technologies and Cardiff Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioStem Technologies	N/A	N/A	N/A
Cardiff Oncology	-7,733.22%	-82.01%	-64.09%

Valuation & Earnings

This table compares BioStem Technologies and Cardiff Oncology”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioStem Technologies	$301.83 million	0.28	$14.31 million	$0.85	5.94
Cardiff Oncology	$590,000.00	234.05	-$45.85 million	($0.69)	-2.93

BioStem Technologies has higher revenue and earnings than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than BioStem Technologies, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for BioStem Technologies and Cardiff Oncology, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioStem Technologies	0	0	0	0	0.00
Cardiff Oncology	1	1	5	0	2.57

Cardiff Oncology has a consensus price target of $10.10, indicating a potential upside of 400.00%. Given Cardiff Oncology’s stronger consensus rating and higher possible upside, analysts clearly believe Cardiff Oncology is more favorable than BioStem Technologies.

Insider and Institutional Ownership

16.3% of Cardiff Oncology shares are held by institutional investors. 7.7% of Cardiff Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility & Risk

BioStem Technologies has a beta of -0.33, meaning that its share price is 133% less volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500.

About BioStem Technologies

BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.

About Cardiff Oncology

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.